Work

Abstract PS5-07-30: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-07-30

Authors: M. P. Goetz, S. A. Wander, T. Bachelot, G. Curigliano, A. de Nonneville, E. N. Gal-Yam, K. Jhaveri, S. L. Sammons, S. Shen, C. J. Twelves, G. Gasper, P. V. Plourde, D. J. Portman, S. Damodaran

Institutions: Mayo Clinic, Massachusetts General Hospital, Centre Léon Bérard, European Institute of Oncology, Institut Paoli-Calmettes, Sheba Medical Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Leeds Teaching Hospitals NHS Trust, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129581762

Cites:

Cited by:

Related to: